RxDoctor Payments Data

Lisa Chang, DO

Family Medicine · Astoria, NYNPI 1164743308

Payments from drug & device makers

$1,093in general payments, 2019–2025

Across 57 payments — averaging $19.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$304
  • Novo Nordisk$220
  • Amgen$158
  • Cequr Corporation$140
  • Pfizer$76
  • Sanofi Pasteur Inc.$46
  • plus $148 from 7 others

What the payments were for

  • Food & beverage$1,093100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,093 in reported general payments places this provider in the 65th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$76,551
Medicare patients
147
Services billed
1,053

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide70$71,891
JanuviaSitagliptin Phosphate59$70,388
EliquisApixaban50$48,943
FarxigaDapagliflozin Propanediol38$37,264
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$28,863
TradjentaLinagliptin27$28,425
JardianceEmpagliflozin13$21,635
VascepaIcosapent Ethyl20$14,522
XareltoRivaroxaban24$13,088
Breo ElliptaFluticasone/Vilanterol17$6,341
Atorvastatin Calcium448$4,304
Lantus SolostarInsulin Glargine,hum.Rec.Anlog37$4,188
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$4,175
Levothyroxine Sodium197$2,557
Albuterol Sulfate HfaAlbuterol Sulfate84$2,478

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$220$71,89170 claims
MerckJanuvia$41$70,38859 claims
PfizerEliquis$76$48,94350 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,321 family medicine providers in New York.

Other family medicine in Astoria

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →